NCT05299931View on ClinicalTrials.gov

An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients with Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation Study

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Crohn Disease
Interventions
DRUG

Ustekinumab

dose escalation from every 8 weeks to every 4 weeks only in arm 2

Trial Locations (1)

1930

Ingrid Arijs, Zaventem

All Listed Sponsors
collaborator

Janssen Cilag N.V./S.A.

INDUSTRY

lead

Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

OTHER